US Patent Issued to ALLIFE MEDICINE (ZHUHAI) on Feb. 10 for "Efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and use" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,898, issued on Feb. 10, was assigned to ALLIFE MEDICINE (ZHUHAI) Ltd. (Zhuhai, China).

"Efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and use" was invented by Lida Wu (Zhuhai, China) and Yuchun Gu (Zhuhai, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSE...